Prognostic risk assessment model for alternative splicing events and splicing factors in malignant pleural mesothelioma.

This study provides the first comprehensive analysis of the prognostic value of AS events and SFs in MPM. The SF-AS regulatory network established in this study and our drug sensitivity analysis using the SF model may provide novel targets for pharmacological studies of MPM.